<DOC>
	<DOC>NCT02443688</DOC>
	<brief_summary>This study is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of CTX-4430 administered once-daily for 48 weeks for treatment of CF.</brief_summary>
	<brief_title>EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult CF Patients</brief_title>
	<detailed_description>This study is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of CTX-4430 administered once-daily for 48 weeks for treatment of CF. A total of 195 pulmonary CF patients that meet all the inclusion and no exclusion criteria and provide written informed consent will be randomized to receive 50 mg CTX-4430, 100 mg CTX-4430, or placebo in a 1:1:1 ratio. Follow-up visits will be conducted approximately every 4 weeks from Week 4 to Week 52 (4 weeks after completion of treatment).</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>FEV1 â‰¥50 percent predicted at Screening At least 1 pulmonary exacerbation in the 12 months before Screening Pregnant or nursing women Medical condition that is unstable, could be adversely impacted by participation in the study, or could impact assessment of the study results History of organ transplantation History of alcoholism or drug abuse within 2 years before Screening Regular use of a highdose NSAID within 60 days before Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>